In the first therapeutic vaccination trial for NPC, 16 patients with residual disease received four cycles of autologous monocyte-derived dendritic cells (DC) loaded with LMP2-specific CD8+ T-cell epitope peptides (126). The gene discussed is PSMB9; the disease is nasopharyngeal carcinoma.